Abstract
Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.
Original language | English (US) |
---|---|
Pages (from-to) | 1171-1181 |
Number of pages | 11 |
Journal | International Journal of Clinical Oncology |
Volume | 24 |
Issue number | 10 |
DOIs | |
State | Published - Oct 1 2019 |
Externally published | Yes |
Keywords
- CTLA-4
- Drug reactions
- Immune checkpoint inhibitor
- Melanoma
- PD-1
- Sarcoidosis-like granuloma
ASJC Scopus subject areas
- Surgery
- Hematology
- Oncology